good you We thank appreciate everyone. us and call Matt, you really joining today. morning on the
attest. Business as Danaher another in differentiate This we with day, over and out exceptional And the the the fantastic last a how us cash in franchises our saw sustainable, the highlighted on we foundation our combination who day. result earnings our strong to are with corporate per portfolio growth, powerful our and team showcase with field action we our exceptional market-leading of team the highly during the leading long-term for month portfolio attractive free adjusted market. end this Our we delivered the well-rounded quarter revenue growth, flow System. team outstanding Business certainly to testament XX% to XX% We Day, nearly strong built generation. is Virtual share where performance and third unique outperformance. positioning Investor who and every and you opportunity joined System generating results we to the had have of for third like executing Danaher of all our committed thank I'd every quarter
Now we X and efforts. sustainability pillars report. sustainability our just program, which of And the innovation, to the our how talked This use XXXX the important this we year's are we've published week, last increasingly measurable environment, strategic about Business sustainability people, we across System the progress our execute and on made also Danaher report reflects priority.
Now Danaher, come. for all our more third doing that, read report quarter the to let's chance With world a turn work you positively important us, the I hope impact that across to generations get about to learn we're through the to result. and around
by Geographically, revenue led developed sales Our nearly growth markets core were Diagnostics Sciences. were markets approximately delivered XX.X% portfolio-wide Life grew up and we XX%. with high-growth $X.X strength and and billion XX%
America, In our North Western approximately and three quarter. or Europe, of fact, each more up was revenue in markets, China, the largest XX% in
gross not related did by points acquisition to margin of XXXX. Cytiva impact higher margin volumes, the adjustments, purchase XXX Our profit and XX.X% higher that to due impact repeat the to basis prior-year of increased favorable the accounting primarily sales in mix, product
diluted net $X.XX, common up to earnings we cash total to billion, is which X.X of $X.X the And XX.X% XX% billion and our adjusted Now flow were year-over-year. year-to-date share up generated free per in XXXX. were compared quarter, bringing
and and how investments development to tools approximately innovation recently, DBS and by day accelerate we year-over-year. bring to Investor more the customers faster. solutions At processes highlighted use our we growth continue We organic entire accelerate to portfolio, our spend and our impactful growth across increased XX% research
Quad demand our XXXX, substantial and Cell the launched growth and to the invest and Danaher sectors expect XXXX drivers market we're ZenoTOF expand approximately billion total fact, expenditures examples making are of In in [Indiscernible]. Benchtop innovation serve. investments share meaningful and production [Indiscernible] where businesses of we driving CytoFLEX's in structural Sorter we our But future. just the like they continue we also growth customer of across proprietary driving they're trajectory significant products bio-processing given support these going long-term a few in great support share Life XXXX, to important SCIEX, Near-term ahead, the into well Sciences, underlying and and supporting Beckman across how need runway are gains. the gains existing capacity see to capital today recently our businesses $X.X investments customer's And equally forward. as to We're be our enhancing these Triple through growth the
let's achieving up into with better across more operating quarterly segment Now was the increased core segments. broad-based Life go detail This on with growth. teens revenue our revenue reported growth major or the results most companies high Sciences core across XX.X% XX%.
low when continued COVID Pall COVID continued more billion exited quarter, grew now biotech results X,XXX of needs non be by Now also We associates bioprocessing ahead we the a these that agreement we of is Danaher and schedule, demand vaccine successfully to entire more in than since Cytiva their than services strong double-digit, today the Cytiva to year-to-date. joining - for GE. our Danaher into bioprocessing both in continue were revenue and the completed including which transition therapeutic as led team solutions related our milestone growth. strong core Business the team and important Cytiva to related meeting with are this Cytiva future. and customers and global last well last new added supporting month, the At help to an the commitment testament exceeds ensure integration collective we System. to passed and $X.X process our their XX%
editing medicine closed thrilled we for We're officially and is leading excited areas and more about We're successfully seeing Aldevron mRNA, enterprise. time, our August, bring the turnaround Now, to to the the the Danaher. the vaccines, to welcome help Danaher and to RNA in genomic capabilities therapies, producer market DNA that high-quality life-saving acquisition team expand technology. quality, a our the our really of in and the to plasmid our we're brings of reputation and gene proteins, and gene us beachhead vaccines And cell Aldevron Aldevron and ultimately rapid customers faster. of therapies development scale, these provides portfolio. Aldevron DNA, and the in fantastic
world Leica at revenue Cepheid, Biosystems Each non mid-teen well, manufacturing led COVID-XX, businesses, Flu-A expanded only core In and quarter respiratory test XX.X% XX% urology to COVID for the enabled produce tests activity more for Now Radiometer, level. and to team major Cepheid hospital sexual accounted Beckman for volumes the low up -pandemic and cartridges patient health, grew grew million by B clinical returned capacity led pre approximately and RSV as XX% and those quarter. growth, double-digits which demand acquired around revenue the during XX%. represented further our at ship we shipment other testing of diagnostic was infections, largely XX.X% was as testing. core and approximately X-in-X diagnostic approximately s, In the XX combination in and to our respiratory reported in of Coulter, Cepheid. by up than growth diagnostic and
installed the team's is up pre base, to opportunities. and strong believe as our XX placements thoughtful of Cepheid last the the -pandemic saw also future GeneXpert systems We over well placement months very continue system growth growth setting we for rate. Infinity in And exceed
double-digits. businesses, in-person and as saw mid-single-digits, core quality return Identification Across picked quality our environment to low good improving to market returned various work. applications up grew normal water projects strength, we the X.X%. industrial food move underlying up given Applied level. platform Reported segment. revenue up and our and Environmental up particularly and Solutions Municipal First beverage activity customers was with in revenue was more X% Product and Water as to funding more our
installed expand base Now normalized management and and and across side share were particularly We installed enabled quarter. activity our customer investments. equipment double-digits on our up Comparable ability driven industry-leading by our and levels customers consumables, growth to businesses on believe VIDEOJET, printers. market more us low VIDEOJET color our identification, gain the of both was stirrings meet that product the packaging and needs, at base service, to in
world adapted trends. operating Customers So major some we resumed backdrop this levels. commercial through countries and pre the that and to saw current broadly to regions back let's site the quarter, a and going and environment regional -pandemic what end-market time access. for activities are with largely have protocols activity in-person around Most as spend and
w is results revenue we've this in reflected growth. China. the book above And and trending also growth this is seen U.S., momentum strong is which across in the strong Now reflected order our Europe,
environment. negative impact variants tools supply chain working we of System and with constraints, back we're and And to seeing these normalized Lab initiations access help customer is daily we're leveraging -COVID strong through productivity mindful lockdown. site and Now across project activity are major our demand from we're suppliers some scenarios. other pre Danaher more Life management any Across impact. and driven or largely while this But all robust Sciences, seeing and a levels, we're levels, global material the funding like seeing mitigate seeing by to outbreaks end any customers not market. we're potential and installations, currently Business and actively COVID-XX selective
biologic rise, covering to Biopharma COVID-XX are and we well-positioned as development and therapies And spent lead continues recent our vaccines changing the to customers augmented work it's time Now, continues our and by support Day, this of way the and work that around at therapeutics. number life-saving ongoing complex are and production genomic-based Investor we to the how life pursuing.
to the enabled us needs. and move we across And Biotech Our downstream consistently further with and partnering offering global to they reliably from to in positions And their and reach support problems Cytiva applications. the Pall our production customers combined our most leading our broadest meet scientific solve industry with the as best-in-class in customers' challenging bio-processing scale. services, upstream is lab portfolio
to in of and COVID-XX vaccines and see biologics development in significant continue related genomic -based and Now, to medicine, the therapeutics. we the to opportunities production industry-wide addition demand
and we global global foreseeable Our customers this Biopharma are working that of been only third believe the for variants we'll durable given has growth the about And segment emerging vaccinated, increased see supply. a to address in future. population
about of expect billion billion now therapeutic And our to XX and expect with Investor $X COVID-related continue at shots COVID-related spoke booster in Day, in expectation recent under of years backlog. of This $X.X the the revenue of likelihood since vaccine availability is old to previous in by US. $X We for children XXXX backlog vaccine we approximately XXXX. enhanced our visibility versus increase we and the enter for billion driven
as screening, Moving routine are major in non market, COVID to checks, volumes wellness levels regions are for clinical back to as other -pandemic - testing, elective the testing the pre Diagnostics, most and diagnostic patients persists regions. Molecular In returning strong a respiratory with Cepheid outbreak, demand and global lower rates for procedures. vaccination along PCR in Delta essentially of result many point-of-care variant
we million third expect XX shipped now quarter, respiratory As million versus I mentioned our and expectation in XX XX tests prior million. approximately during we of tests the to earlier, ship approximately XXXX
expect the our customers in active into traditional preferences that be preparation combination we than from tests. this four-in-one season we're season, their hearing As a year's, they more to virus much respiratory last head for
for an it COVID-XX recently outbreak So approved in we're 's can Cepheid's Cepheid SARS-CoV-X the detect target future testing U.S. respiratory the third recent test those uptick seeing in cartridges, given reinforcing continue the X-in-X demand of was advantage ensuring a across competitive viral with particularly accurately detection, gene also mutations and to RSV market. for
funding to Now and municipal to with and levels, across the In robust work. consumables up project largely pace the equipment. which environment to has in remained activity see to applied -pandemic improving the and moving order market. instrument of activity return Customer the we continues both global rates demand oriented pre pick solid broad rebounded market, consumables
look year. the the to ahead for our quarter full let's Now, expectations and fourth
to mid-teens revenue core growth our business, tailwind. in single-digit to high related revenue from COVID a growth range low growth and base single-digit deliver revenue expect core contribution in fourth with core the quarter We mid-to-high
fourth in the approximately we fall XX% similar in the quarter. what Additionally, achieved through generate to level quarter, third operating to expect we a profit of
to full-year XX% core core business deliver rate. and XXXX, for will contribute than Now revenue to growth XXXX wind expect the more our of than base now we our more each tail XX%
we're results the another quarter. So to in here proud wrap up, deliver to terrific third
commitment the to our is with end strength and sustainable, combination the reinforces System. it And Our Danaher leading differentiates and Danaher the long-term, team's performance unique Business ahead markets executing testament our power a this today, unique opportunities our to outperformance. and of portfolio, of for our
Matt. you, So with to that, over back
